PR Newswire: news distribution, targeting and monitoring
 

Valeant Pharmaceuticals and Gradient Analytics Settle Lawsuit

 

TORONTO, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Gradient Analytics, Inc. and Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) formerly known as Biovail Corporation, have agreed to settle Gradient's Arizona action against Valeant for malicious prosecution arising out of two earlier actions filed by Biovail and its shareholders in state and federal courts in New Jersey.  Gradient was represented by Michael O. Kassak, Esquire of White and Williams LLP in both the Arizona malicious prosecution action and the earlier New Jersey lawsuits.

"The initiation of litigation against Gradient, its founders Dr. Carr Bettis and Dr. Donn Vickrey, and others in 2006 by Biovail's management at the time was regrettable.  We would like to put this incident behind us," stated J. Michael Pearson, Valeant's chief executive officer.  "With the merger between Valeant and Biovail now complete and a new management team in place, we have the opportunity to settle this matter and, instead, focus all of our efforts on growing Valeant's core businesses and enhancing value for our shareholders."  

Gradient's President and CEO Tom Barrett said:  "Our business, founders and employees suffered significantly as a result of the actions of Biovail, its attorneys, private investigators and public relations agents. However, we are pleased to put this matter behind us and move forward. As has been the case throughout this trying period, we remain resolute in our right to freely express our opinions about publicly traded companies and will continue to do so in the future."

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Laurie W. Little

949-461-6002

laurie.little@valeant.com      



(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101025/LA87217LOGO)

     

SOURCE Valeant Pharmaceuticals International, Inc.

Back to top

RELATED LINKS
http://www.valeant.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

Featured Video

 
  • Print
  • Email
  •   RSS
  • Share it  
  • Blog it  
  • Blog Search  

More in These Categories

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Free Investing Newsletter from Investor Uprising!

Learn to navigate the world's financial system and profit from leading companies.  

Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".

Advanced Search
Search
  
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire